Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Finished Goods (2016 - 2025)

Historic Finished Goods for Amphastar Pharmaceuticals (AMPH) over the last 11 years, with Q3 2025 value amounting to $37.7 million.

  • Amphastar Pharmaceuticals' Finished Goods rose 1169.89% to $37.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.7 million, marking a year-over-year increase of 1169.89%. This contributed to the annual value of $39.4 million for FY2024, which is 5814.11% up from last year.
  • Amphastar Pharmaceuticals' Finished Goods amounted to $37.7 million in Q3 2025, which was up 1169.89% from $41.6 million recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Finished Goods registered a high of $41.6 million during Q2 2025, and its lowest value of $14.5 million during Q1 2022.
  • Over the past 5 years, Amphastar Pharmaceuticals' median Finished Goods value was $24.9 million (recorded in 2023), while the average stood at $25.9 million.
  • In the last 5 years, Amphastar Pharmaceuticals' Finished Goods plummeted by 2262.0% in 2022 and then surged by 9134.68% in 2023.
  • Over the past 5 years, Amphastar Pharmaceuticals' Finished Goods (Quarter) stood at $17.7 million in 2021, then grew by 6.97% to $18.9 million in 2022, then skyrocketed by 31.99% to $24.9 million in 2023, then skyrocketed by 58.14% to $39.4 million in 2024, then fell by 4.34% to $37.7 million in 2025.
  • Its last three reported values are $37.7 million in Q3 2025, $41.6 million for Q2 2025, and $38.4 million during Q1 2025.